Scleroderma (Systemic Sclerosis)

Table of Contents

  1. Overview
  2. Classification: Limited vs Diffuse Systemic Sclerosis
  3. Raynaud's Phenomenon: The First Sign
  4. Skin Manifestations
  5. Internal Organ Involvement
  6. Diagnosis and Monitoring
  7. Treatment: Disease-Modifying Therapies
  8. Living with Scleroderma
  9. Complementary and Supportive Approaches
  10. References & Research
  11. Connections
  12. Featured Videos

Overview

Scleroderma — from the Greek for "hard skin" — is a chronic autoimmune connective tissue disease. Its hallmarks are progressive skin thickening and fibrosis, vascular abnormalities (particularly Raynaud's phenomenon, which affects more than 90% of patients), and in systemic forms, damage to internal organs including the lungs, heart, kidneys, and gastrointestinal tract.

Scleroderma is not a single disease but a spectrum. The word refers both to a purely skin-limited form (morphea, covered separately on the Morphea page) and to two systemic forms that are the focus of this article: limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc).

In the United States, scleroderma affects roughly 20–30 people per 100,000, translating to approximately 300,000 Americans living with the condition. Women are affected three to four times more often than men, and onset typically occurs between ages 30 and 60. Men and Black women tend to develop more severe, diffuse disease with greater organ involvement.

There is no cure. But with modern targeted therapy, many patients live for decades with manageable disease. Early diagnosis, careful monitoring, and prompt treatment of organ complications are the keys to a good outcome.

Classification: Limited vs Diffuse Systemic Sclerosis

Limited Cutaneous Systemic Sclerosis (lcSSc)

In lcSSc, skin thickening is confined to areas distal to the elbows and knees, plus the face and neck. The hands, forearms below the elbow, lower legs below the knee, and face are involved; the trunk is spared.

lcSSc was formerly called CREST syndrome, an acronym capturing its main features:

The antibody most associated with lcSSc is anti-centromere antibody (ACA), found in 70–80% of patients. lcSSc tends to progress more slowly than dcSSc and carries a better overall prognosis. However, pulmonary arterial hypertension (PAH) is a serious late complication — it develops in 10–15% of lcSSc patients and can be fatal if undetected. Gastrointestinal disease is also very common.

Diffuse Cutaneous Systemic Sclerosis (dcSSc)

In dcSSc, skin thickening extends proximal to the elbows and knees, involving the upper arms, thighs, and trunk. This is the more aggressive form.

Key antibodies in dcSSc include:

dcSSc is characterized by rapidly progressive skin fibrosis in the first 3–5 years after onset. Patients face higher risks of renal crisis, severe interstitial lung disease, and cardiac involvement than those with lcSSc. Early referral to a specialist center experienced in scleroderma is essential.

Overlap Syndromes

Scleroderma does not always present in a pure form. Some patients have features of scleroderma alongside other autoimmune diseases:

Back to Table of Contents

Raynaud's Phenomenon: The First Sign

Raynaud's phenomenon is episodic vasospasm of the small arteries supplying the fingers (and sometimes toes, ears, or nose) triggered by cold exposure or emotional stress. It produces a characteristic triphasic color change:

  1. White (pallor) — vasospasm cuts off blood flow; fingers turn white and feel numb
  2. Blue (cyanosis) — deoxygenated blood pools; fingers turn blue or purple
  3. Red (reperfusion) — blood rushes back; fingers turn red and throb or burn

Raynaud's affects over 90% of people with scleroderma — and critically, it often precedes other features by years. The mean interval between onset of Raynaud's and development of skin changes is 7–10 years. This window is an opportunity for early diagnosis.

Primary vs Secondary Raynaud's

Primary Raynaud's (no underlying disease) is common, especially in young women. It is mild, does not cause tissue damage, and is generally benign. Secondary Raynaud's — associated with scleroderma or other connective tissue diseases — is more severe, can cause digital ulcers, pitting scars at the fingertips, and in serious cases, gangrene.

Nailfold capillaroscopy — a simple, non-invasive microscopic examination of the tiny blood vessels at the base of the fingernail — can distinguish primary from secondary Raynaud's. An abnormal "scleroderma pattern" showing dilated, distorted capillary loops and avascular (capillary-free) areas strongly suggests an underlying connective tissue disease, even before other symptoms appear.

Managing Raynaud's in Scleroderma

Behavioral measures first: avoid cold environments; dress in layers with particular attention to the body core (warming the trunk helps vessels relax in the hands); use insulated gloves, hand warmers, and battery-powered heated gloves; avoid smoking (nicotine is a potent vasoconstrictor).

Vasodilator medications:

Digital ulcers — painful open sores on fingertips — are a major cause of disability in scleroderma. Bosentan (an endothelin receptor antagonist) is FDA-approved to reduce new digital ulcer formation.

Back to Table of Contents

Skin Manifestations

Skin changes in scleroderma follow a three-phase progression that can unfold over months to years.

Edematous Phase

The earliest skin change is puffy, swollen fingers — sometimes called "sausage fingers" — caused by non-pitting edema. The skin feels tight but can still be pinched. This phase is easily confused with arthritis, heart failure, or other causes of hand swelling.

Induration Phase

Gradually, the skin thickens and hardens. The skin can no longer be pinched or lifted off the underlying tissue. Finger movement becomes restricted. Sclerodactyly — thickened, tapered fingers with a shiny surface — develops. The degree of skin thickening is measured by the Modified Rodnan Skin Score (mRSS), which assesses skin thickness at 17 body sites on a scale of 0–51; higher scores indicate more extensive disease and are used to monitor treatment response.

Other skin features during this phase include:

Atrophic Phase

In later disease, the skin may paradoxically soften and thin as fibrosis "burns out." However, structural damage — flexion contractures fixing the fingers in a bent position, pitted fingertip scars, and loss of normal skin folds — persists.

Facial Changes

Scleroderma affects the face in characteristic ways. Perioral radiating furrows — radial lines around the mouth resembling purse-string stitching — are distinctive. Microstomia (reduced mouth opening) can make eating, speaking, and dental hygiene difficult. The face takes on a mask-like, expressionless quality as skin tightening limits normal facial movement.

Hair and Nails

Diffuse hair thinning and loss can occur. Nail changes include pitting, brittleness, and pterygium (thickening and overgrowth of the nail folds).

Back to Table of Contents

Internal Organ Involvement

It is the internal organ involvement — not the skin changes — that most threatens life in scleroderma. The two leading causes of scleroderma-related death are pulmonary complications (ILD and PAH) and cardiac disease.

Lungs

Interstitial lung disease (ILD) — scarring of the lung tissue — is the most common serious complication, affecting 35–52% of all scleroderma patients and up to 70% of those with dcSSc who carry the anti-Scl-70 antibody. ILD causes progressive shortness of breath and dry cough. High-resolution CT (HRCT) of the chest shows ground-glass opacity and, later, honeycombing. Pulmonary function tests (PFTs) reveal reduced forced vital capacity (FVC) and a low diffusing capacity for carbon monoxide (DLCO).

Approved treatments for SSc-ILD include:

Pulmonary arterial hypertension (PAH) — high blood pressure in the arteries of the lungs — is a distinct complication more common in lcSSc (anti-centromere positive) patients. It affects 8–12% of scleroderma patients. PAH causes progressive right heart failure. Definitive diagnosis requires right heart catheterization. PAH is treated with a combination of:

Gastrointestinal Tract

GI involvement affects 80–90% of scleroderma patients and is the most common internal organ manifestation. Almost any part of the GI tract can be affected:

Kidneys: Scleroderma Renal Crisis

Scleroderma renal crisis (SRC) is a medical emergency. It occurs in approximately 5–10% of patients — predominantly those with early, rapidly progressive dcSSc and anti-RNA Pol III antibody. SRC presents as sudden-onset severe hypertension (often called "flash hypertension") with rapidly rising creatinine and, if untreated, renal failure.

Treatment: ACE inhibitors are life-saving and must be started immediately. Captopril or enalapril should be given even if potassium is rising and even if creatinine is worsening — in SRC, ACE inhibitors save the kidneys by treating the underlying vasospasm. Stopping them for rising creatinine (as one would in other causes of renal failure) is incorrect and dangerous in this context.

Critical warning: corticosteroids increase the risk of scleroderma renal crisis and should be avoided in dcSSc patients whenever possible, particularly doses above 15 mg/day of prednisone equivalent.

Heart

Cardiac involvement may be subclinical or manifest as arrhythmias, pericarditis, diastolic dysfunction, or myocardial fibrosis. Regular monitoring with ECG and echocardiogram is important, particularly in dcSSc. Inflammatory myocarditis occurs in overlap syndromes.

Joints and Muscles

Arthralgia and morning stiffness are common. Flexion contractures reduce hand function significantly. Inflammatory myopathy (muscle inflammation causing weakness) occurs in overlap syndromes and responds to immunosuppression.

Back to Table of Contents

Diagnosis and Monitoring

2013 ACR/EULAR Classification Criteria

The most widely used diagnostic framework is the 2013 ACR/EULAR Classification Criteria (van den Hoogen et al., PMID 24092682). A total score of 9 or more classifies a patient as having systemic sclerosis. Key criteria and their point values:

Key Antibody Tests

Serological testing guides both diagnosis and prognosis:

Baseline Workup and Monitoring

At diagnosis, the following assessments establish an organ-by-organ baseline:

After baseline, monitoring is ongoing: PFTs every 6–12 months; echocardiogram annually; HRCT every 1–2 years in patients with ILD; frequent blood pressure checks in early dcSSc.

Back to Table of Contents

Treatment: Disease-Modifying Therapies

There is currently no cure for scleroderma. Treatment aims to slow skin and organ fibrosis, manage symptoms, and promptly treat organ-specific complications. Treatment is ideally managed at centers with expertise in scleroderma.

Skin and Immune Disease

Autologous Hematopoietic Stem Cell Transplantation (HSCT)

For selected patients with early, severe dcSSc at high risk of organ failure, autologous HSCT (using the patient's own stem cells after intensive immune suppression) has shown benefit in two major randomized trials: the ASTIS trial and the SCOT trial (Sullivan et al., PMID 29298160). HSCT carries significant treatment-related mortality (approximately 3–10%) and is only appropriate at experienced transplant centers for carefully selected patients who have failed or are unlikely to respond to conventional therapy.

ILD-Specific Treatment

As noted in the organ involvement section: nintedanib (Distler et al., PMID 31112386) + MMF are the current pillars. Tocilizumab adds to this armamentarium. Ongoing clinical trials are investigating anti-fibrotic agents targeting TGF-beta and FGF pathways.

Raynaud's and Digital Ulcers

See the Raynaud's section above for full management. Bosentan (an endothelin receptor antagonist) is specifically approved for reducing new digital ulcer formation in scleroderma.

PAH Treatment

PAH requires specialist management with combination endothelin receptor antagonist + PDE5 inhibitor as a standard starting approach, escalating to prostacyclin analogs as needed. Regular right heart catheterization monitors treatment response.

Gastroprotection and GI Management

High-dose PPI therapy (omeprazole or pantoprazole 40 mg twice daily) is essential for virtually all patients with scleroderma-related GERD. Promotility agents (metoclopramide for short-term acute use; erythromycin for gastroparesis exacerbations) may help. Rotating antibiotics — rifaximin, metronidazole, ciprofloxacin in alternating courses — are used for SIBO-related symptoms. Nutritional support, including parenteral nutrition in severe cases, may be required for malabsorption.

Back to Table of Contents

Living with Scleroderma

Scleroderma requires significant day-to-day adaptation. Understanding these practical challenges helps patients and families plan effectively.

Hand Function

Physical and occupational therapy should start early — before contractures become fixed. Paraffin wax baths help soften stiff fingers and improve range of motion. Regular hand exercises (making a fist, finger spreading, wrist circles) are important to maintain function. Adaptive tools — jar openers, ergonomic pens, button hooks, electric can openers — reduce the effort required for daily tasks. Splints can help maintain hand position during sleep.

Mouth and Dental Health

Microstomia (reduced mouth opening) makes dental hygiene and dental treatment difficult. A program of facial stretching exercises — opening the mouth as wide as possible, smiling broadly, puffing out cheeks — slows the loss of mouth opening. Wide-bristle or electric toothbrushes help. Regular dental checkups are critical because scleroderma-related dry mouth (when Sjögren's overlap exists) accelerates tooth decay.

Nutrition and Eating

GI involvement can severely impact nutrition. Small, frequent meals are better tolerated than three large meals for both reflux and gastroparesis. Soft or pureed foods ease dysphagia. A high-protein diet compensates for malabsorption. Sitting upright for at least an hour after meals and elevating the head of the bed 6–8 inches reduces nighttime GERD. Referral to a registered dietitian experienced in GI disorders is valuable. Vitamin D deficiency is common in scleroderma and supplementation is usually appropriate.

Managing Cold Exposure

For patients with Raynaud's, cold is the primary trigger for attacks. Practical strategies include:

Pain and Fatigue

Fibromyalgia co-exists with scleroderma in approximately 20% of patients, amplifying pain and fatigue independent of disease activity. Low-dose naltrexone (LDN) is used off-label by some rheumatologists for pain and fatigue in scleroderma with promising anecdotal reports, though large trials are lacking. Gabapentin and pregabalin help with neuropathic pain and sleep disturbance. Fatigue is one of the most disabling symptoms; pacing strategies, energy conservation techniques, and gentle aerobic exercise all help.

Emotional Health

Depression and anxiety affect up to 50% of people with scleroderma. The combination of chronic pain, significant physical changes (skin thickening, facial changes, hand deformity), unpredictable disease course, and functional limitations is psychologically demanding. Cognitive behavioral therapy (CBT) is effective for both depression and pain in chronic disease. Peer support through the Scleroderma Foundation (scleroderma.org) connects patients with others who understand the experience.

Pregnancy

Pregnancy is possible for many women with scleroderma but requires careful planning. Pulmonary arterial hypertension is a contraindication to pregnancy — the mortality risk for mother and baby is extremely high. Women with moderate-to-severe disease should receive pre-conception counseling from a rheumatologist experienced in scleroderma. Scleroderma renal crisis can be precipitated by pregnancy. Disease-modifying medications (MMF, methotrexate, cyclophosphamide) must be stopped before conception.

Employment and Disability

Many patients with scleroderma remain employed, particularly in lcSSc. Workplace accommodations — ergonomic workstations, flexible hours for fatigue management, work-from-home options in cold climates — make a significant difference. For those who cannot work, the Social Security Disability process is available; rheumatologist documentation of functional limitations is critical.

Back to Table of Contents

Complementary and Supportive Approaches

Complementary approaches in scleroderma target the known pathophysiological drivers — oxidative stress, vascular inflammation, fibrosis, and immune dysregulation — and support overall well-being. None replaces conventional treatment, but several have a meaningful evidence base.

Antioxidants

Oxidative stress plays a documented role in scleroderma pathogenesis, damaging vascular endothelium and driving fibrosis. Several antioxidants have been studied:

Omega-3 Fatty Acids

EPA and DHA from fish oil have anti-inflammatory and mild anti-platelet effects relevant to scleroderma's vascular disease. Some evidence suggests benefit for skin softening in inflammatory diseases. Low-dose aspirin (81 mg daily) also provides anti-platelet protection for digital ischemia.

Herbal and Natural Compounds

Skincare and Physical Therapies

Emollient-rich moisturizers — vitamin E cream, shea butter, lanolin — help maintain skin flexibility and reduce cracking. Lymphedema massage by a trained therapist can reduce edematous swelling in the fingers during the early edematous phase. Gentle skin massage with moisturizer improves circulation and may soften thickened skin over time.

Exercise

Regular aerobic exercise — walking, swimming, cycling — is safe in scleroderma and demonstrably beneficial. It improves functional capacity, reduces fatigue, supports cardiovascular health, and may improve mood and sleep. The Arthritis Foundation's evidence-based exercise programs are appropriate starting points. Stretching and range-of-motion exercises are particularly important for maintaining hand and facial mobility.

Mind-Body Practices

Yoga and tai chi combine gentle movement with breathing and relaxation — both relevant for scleroderma patients managing Raynaud's triggers (breathing and stress) and limited mobility. Mindfulness-based stress reduction (MBSR) has demonstrated benefit for pain, anxiety, and quality of life in multiple chronic inflammatory conditions. Biofeedback — learning to warm the hands voluntarily using visual feedback — has shown modest benefit for Raynaud's in controlled trials.

Back to Table of Contents

References & Research

  1. van den Hoogen F et al., 2013: 2013 Classification Criteria for Systemic Sclerosis — an ACR/EULAR Collaborative Initiative. Ann Rheum Dis. 72(11):1747–1755. PMID: 24092682
  2. Tashkin DP et al., 2006: Cyclophosphamide versus placebo in scleroderma lung disease (SLS I trial). N Engl J Med. 354(25):2655–2666. PMID: 16790698
  3. Distler O et al., 2019: Nintedanib for systemic sclerosis-associated interstitial lung disease (SENSCIS trial). N Engl J Med. 380(26):2518–2528. PMID: 31112386
  4. Khanna D et al., 2016: Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (faSScinate). Lancet. 387(10038):2630–2640. PMID: 27177218
  5. Sullivan KM et al., 2018: Myeloablative autologous stem-cell transplantation for severe scleroderma (SCOT trial). N Engl J Med. 378(1):35–47. PMID: 29298160
  6. Kowal-Bielecka O et al., 2017: Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 76(8):1327–1339. PMID: 28351914
  7. Nihtyanova SI et al., 2012: Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum. 64(10):3209–3218. PMID: 22674003
  8. Wigley FM, 2002: Raynaud's phenomenon. N Engl J Med. 347(13):1001–1008. PMID: 12324556
  9. Herrick AL et al., 2012: Nailfold capillaroscopy as a classification tool for systemic sclerosis. Arthritis Rheum. 64(11):3461–3469. PMID: 22833381
  10. Guillevin L et al., 1999: Systemic sclerosis with overlap syndrome: clinical features and outcome. J Rheumatol. 26(3):522–531. PMID: 10090155

Back to Table of Contents

Connections

Back to Table of Contents